$3.22
-21%Safety Shot, Inc. provides over-the-counter products and consumer products in the United States. The company offers Safety Shot Beverage, an over-the-counter drink that lowers blood alcohol content. It also provides hair loss treatment, vitiligo solution, eczema cream, and sexual wellness products. It sells its products through direct customers, distributors, retailers, and e-commerce websites. The company was formerly known as Jupiter Wellness, Inc. and changed its name to Safety Shot, Inc. in September 2023. Safety Shot, Inc. was incorporated in 2018 and is based in Jupiter, Florida.
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
BNKK • NASDAQ
| Bonk, Inc. Balance Sheet | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
ASSETS | |||||
CURRENT ASSETS | |||||
348.8K | 3.8M | 1.5M | 11.8M | 4.3M | |
282.7K | 1.5M | 2.9M | 2.9M | 0.0 | |
631.5K | 5.3M | 4.4M | 14.7M | 4.3M | |
795.1K | 5.6K | 1.5M | 695.3K | 255.1K | |
283.6K | 5.6K | 26.4K | 695.3K | 255.1K | |
511.6K | 0.0 | 1.5M | 0.0 | 0.0 | |
233.5K | 795.8K | 151.2K | 304.3K | 225.9K | |
920.2K | 1.5M | 116.4K | 617.3K | 215.9K | |
0.0 | 86.2K | 611.3K | 0.0 | 0.0 | |
2.6M | 7.7M | 6.8M | 16.3M | 5M | |
NON-CURRENT ASSETS | |||||
393.7K | 507.3K | 696.5K | 906.4K | 64.7K | |
0.0 | 0.0 | 941.9K | 941.9K | 941.9K | |
4.4M | 4.5M | 291.5K | 739.4K | 559.8K | |
4.4M | 4.5M | 1.2M | 1.7M | 1.5M | |
0.0 | 0.0 | 9.3K | 0.0 | 0.0 | |
4.8M | 5M | 1.9M | 2.6M | 1.6M | |
7.3M | 12.7M | 8.7M | 18.9M | 6.5M | |
LIABILITIES | |||||
CURRENT LIABILITIES | |||||
2.2M | 1.5M | 1.5M | 1.2M | 688.8K | |
2.2M | 1.5M | 1.5M | 1.2M | 688.8K | |
1.7M | 329.6K | 152.2K | 160.5K | 112K | |
5.3M | 1.5M | 2M | 47.5K | 1.3M | |
213K | 214.8K | 164.2K | 118.1K | 23.8K | |
0.0 | 0.0 | 593.2K | 0.0 | 0.0 | |
9.4M | 3.6M | 4.5M | 1.6M | 2.1M | |
NON-CURRENT LIABILITIES | |||||
114.1K | 304.9K | 519.7K | 696K | 6.4K | |
327.1K | 519.7K | 683.8K | 814.1K | 30.1K | |
9.5M | 3.9M | 5M | 2.3M | 2.1M | |
SHAREHOLDERS' EQUITY | |||||
62.6K | 45.6K | 22.3K | 24K | 10.7K | |
110.9M | 73.7M | 53.8M | 51.7M | 11.7M | |
-115.1M | -65.7M | -50.6M | -35.4M | -7.3M | |
2M | 725.2K | 477K | 285K | 0.0 | |
-2.2M | 8.8M | 3.7M | 16.6M | 4.4M | |
-2.2M | 8.8M | 3.7M | 16.6M | 4.4M | |
SUMMARY | |||||
7.3M | 12.7M | 8.7M | 18.9M | 6.5M | |
282.7K | 1.5M | 2.9M | 2.9M | 0.0 | |
5.6M | 2.1M | 2.7M | 861.6K | 1.3M | |
5.3M | -1.8M | 1.3M | -10.9M | -2.9M | |
185,476,000 | 185,476,000 | 185,476,000 | 185,476,000 | 185,476,000 |
BNKK - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-1 S-1 N/A | December 10, 2025 | December 10, 2025 | ||
8-K 8-K 2025 N/A | December 08, 2025 | December 03, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | December 01, 2025 | December 01, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 19, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 07, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 05, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | October 31, 2025 | 2025 | |
8-K/A 8-K/A 2025 (Amended) N/A | October 16, 2025 | August 25, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 14, 2025 | October 08, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 08, 2025 | October 03, 2025 | 2025 |
Continue your BNKK research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.